Institution
Université de Sherbrooke
Education•Sherbrooke, Quebec, Canada•
About: Université de Sherbrooke is a education organization based out in Sherbrooke, Quebec, Canada. It is known for research contribution in the topics: Population & Receptor. The organization has 14922 authors who have published 28783 publications receiving 792511 citations. The organization is also known as: Universite de Sherbrooke & Sherbrooke University.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: It is suggested that GDM has epigenetic effects on genes preferentially involved in the metabolic diseases pathway, with consequences on fetal growth and development, and supportive evidence that DNA methylation is involved in fetal metabolic programming is provided.
Abstract: Offspring exposed to gestational diabetes mellitus (GDM) have an increased risk for chronic diseases, and one promising mechanism for fetal metabolic programming is epigenetics. Therefore, we postulated that GDM exposure impacts the offspring’s methylome and used an epigenomic approach to explore this hypothesis. Placenta and cord blood samples were obtained from 44 newborns, including 30 exposed to GDM. Women were recruited at first trimester of pregnancy and followed until delivery. GDM was assessed after a 75-g oral glucose tolerance test at 24–28 weeks of pregnancy. DNA methylation was measured at > 485,000 CpG sites (Infinium HumanMethylation450 BeadChips). Ingenuity Pathway Analysis was conducted to identify metabolic pathways epigenetically affected by GDM. Our results showed that 3,271 and 3,758 genes in placenta and cord blood, respectively, were potentially differentially methylated between samples exposed or not to GDM (p-values down to 1 × 10−06; none reached the genome-wide significance level...
223 citations
••
University of Pittsburgh1, University of California, Los Angeles2, Imperial College Healthcare3, King Saud bin Abdulaziz University for Health Sciences4, Oklahoma State University Center for Health Sciences5, St. Michael's Hospital6, Monash University7, Paris Descartes University8, University of Amsterdam9, University of Antwerp10, Princess Alexandra Hospital11, Université de Sherbrooke12, University of Western Australia13, University of Toronto14, Wellington Management Company15, University of British Columbia16, University College Dublin17, University of Auckland18, Wellington Hospital19, Utrecht University20, Auckland City Hospital21, St John of God Subiaco Hospital22
TL;DR: A large, international trial that combines features of adaptive platform trials with pragmatic point-of-care trials to determine best treatment strategies for patients admitted to an intensive care unit with severe community-acquired pneumonia is presented.
Abstract: There is broad interest in improved methods to generate robust evidence regarding best practice, especially in settings where patient conditions are heterogenous and require multiple concomitant therapies. Here, we present the rationale and design of a large, international trial that combines features of adaptive platform trials with pragmatic point-of-care trials to determine best treatment strategies for patients admitted to an intensive care unit with severe community-acquired pneumonia. The trial uses a novel design, entitled "a randomized embedded multifactorial adaptive platform." The design has five key features: 1) randomization, allowing robust causal inference; 2) embedding of study procedures into routine care processes, facilitating enrollment, trial efficiency, and generalizability; 3) a multifactorial statistical model comparing multiple interventions across multiple patient subgroups; 4) response-adaptive randomization with preferential assignment to those interventions that appear most favorable; and 5) a platform structured to permit continuous, potentially perpetual enrollment beyond the evaluation of the initial treatments. The trial randomizes patients to multiple interventions within four treatment domains: antibiotics, antiviral therapy for influenza, host immunomodulation with extended macrolide therapy, and alternative corticosteroid regimens, representing 240 treatment regimens. The trial generates estimates of superiority, inferiority, and equivalence between regimens on the primary outcome of 90-day mortality, stratified by presence or absence of concomitant shock and proven or suspected influenza infection. The trial will also compare ventilatory and oxygenation strategies, and has capacity to address additional questions rapidly during pandemic respiratory infections. As of January 2020, REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) was approved and enrolling patients in 52 intensive care units in 13 countries on 3 continents. In February, it transitioned into pandemic mode with several design adaptations for coronavirus disease 2019. Lessons learned from the design and conduct of this trial should aid in dissemination of similar platform initiatives in other disease areas.Clinical trial registered with www.clinicaltrials.gov (NCT02735707).
222 citations
••
TL;DR: It is concluded that AD is associated with altered plasma status of both DHA and other fatty acids unrelated to DHA, and that the lipid class-dependent nature of these differences reflects a combination of differences in intake and metabolism.
Abstract: Alzheimer's disease (AD) is generally associated with lower omega-3 fatty acid intake from fish but despite numerous studies, it is still unclear whether there are differences in omega-3 fatty acids in plasma or brain. In matched plasma and brain samples provided by the Memory and Aging Project, fatty acid profiles were quantified in several plasma lipid classes and in three brain cortical regions. Fatty acid data were expressed as % composition and as concentrations (mg/dL for plasma or mg/g for brain). Differences in plasma fatty acid profiles between AD, mild cognitive impairment (MCI), and those with no cognitive impairment (NCI) were most apparent in the plasma free fatty acids (lower oleic acid isomers and omega-6 fatty acids in AD) and phospholipids (lower omega-3 fatty acids in AD). In brain, % DHA was lower only in phosphatidylserine of mid-frontal cortex and superior temporal cortex in AD compared to NCI (-14% and -12%, respectively; both p < 0.05). The only significant correlation between plasma and brain fatty acids was between % DHA in plasma total lipids and % DHA in phosphatidylethanolamine of the angular gyrus, but only in the NCI group (+0.77, p < 0.05). We conclude that AD is associated with altered plasma status of both DHA and other fatty acids unrelated to DHA, and that the lipid class-dependent nature of these differences reflects a combination of differences in intake and metabolism.
222 citations
••
TL;DR: Improved glycemic control in the elderly patient with NIDDM may have beneficial effects on selective areas of cognition, and this study has found that cognitive function is impaired in elderly patients with non-insulin dependent diabetes mellitus.
Abstract: BACKGROUND A number of studies have found that cognitive function is impaired in elderly patients with non-insulin dependent diabetes mellitus (NIDDM) when compared with age-matched non-diabetic controls. In addition, it has been reported that elderly NIDDM patients who have poor glycemic control have a greater impairment in cognition that elderly NIDDM patients with good control. We conducted the following prospective study to determine if improved glycemic control would result in an improvement in cognitive function in elderly patients with NIDDM: METHODS Sixteen untreated elderly patients with NIDDM underwent a battery of neuropsychologic tests on two occasions, separated by at least two weeks. They were then started on an oral hypoglycemic agent. After they had been on a stable dose of medication for 6 months the neuropsychologic tests were repeated. RESULTS Fasting glucose decreased significantly after treatment (before: 13.8 +/- 1.2 mmol/l; after 8.4 +/- 0.4 mmol/l, p < .01). After 6 months of treatment patients had improvement in their scores on the Grooved Pegboard, Trail Making-Part A, Stroop-Word Naming, Cued Recall and Picture Arrangement tests (all p < .05). CONCLUSIONS Improved glycemic control in the elderly patient with NIDDM may have beneficial effects on selective areas of cognition.
222 citations
••
TL;DR: Analysis of the results showed that web site quality had a positive impact on the cognitive appraisal of situational state, which influenced five of the six emotions of the proposed model: liking, joy, pride, dislike, and frustration.
222 citations
Authors
Showing all 15051 results
Name | H-index | Papers | Citations |
---|---|---|---|
Masashi Yanagisawa | 130 | 524 | 83631 |
Joseph V. Bonventre | 126 | 596 | 61009 |
Jeffrey L. Benovic | 99 | 264 | 30041 |
Alessio Fasano | 96 | 478 | 34580 |
Graham Pawelec | 89 | 572 | 27373 |
Simon C. Robson | 88 | 552 | 29808 |
Paul B. Corkum | 88 | 576 | 37200 |
Mario Leclerc | 88 | 374 | 35961 |
Stephen M. Collins | 86 | 320 | 25646 |
Ed Harlow | 86 | 190 | 61008 |
William D. Fraser | 85 | 827 | 30155 |
Jean Cadet | 83 | 372 | 24000 |
Vincent Giguère | 82 | 227 | 27481 |
Robert Gurny | 81 | 396 | 28391 |
Jean-Michel Gaillard | 81 | 410 | 26780 |